Raymond James lowers MSCI stock price target to $700 on market concerns
Raymond James has lowered its price target for MSCI Inc. (NYSE:MSCI) to $700 from $710, while maintaining a Strong Buy rating due to anticipated headwinds from a March equity market downturn. Despite the reduced target, MSCI remains Raymond James' top pick within Information Services, citing strong sales momentum, limited AI risk, solid fundamentals with 9.75% revenue growth, and aggressive share buybacks by management. The firm also highlights MSCI's strategic acquisitions and partnerships aimed at enhancing its financial services offerings.
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead Sciences is acquiring Tubulis GmbH for $3.15 billion upfront, with potential additional milestone payments, to bolster its oncology pipeline with TUB-040, an antibody-drug conjugate for ovarian cancer. This acquisition follows other recent deals, including Ouro Medicines and Arcellx, highlighting Gilead's strategy to expand its portfolio in oncology and autoimmune diseases. Despite the strategic acquisitions, Gilead's stock (GILD) showed short-term weakness but maintained a positive long-term outlook.
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Merck has officially commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc. for $53.00 per share, following a definitive agreement announced on March 25, 2026. The tender offer is set to expire on May 4, 2026, and is subject to conditions including the tender of over 50% of Terns' shares and regulatory approvals. This acquisition is expected to close in the second quarter of 2026, making Terns a wholly owned subsidiary of Merck.
Hologic goes private in $79 per share buyout by Blackstone, TPG
Hologic Inc. has transitioned to private ownership in a $79 per share buyout by funds managed by Blackstone and TPG, with minority investments from Abu Dhabi Investment Authority and GIC. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders received $76 per share in cash plus a non-tradable contingent value right of up to $3 per share, dependent on future Breast Health business revenue goals.
MetLife Investment Management Hires New Head of Real Estate, Agriculture From Blackstone
MetLife Investment Management has appointed Andrea Drasites as its new global head of real estate and agricultural finance, effective October 1. She will oversee $108.9 billion in assets and succeeds Robert Merck. Drasites joins MIM from Blackstone’s real estate group, where she served as a senior managing director for 13 years.
The funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC along with Abu Dhabi Investment Authority and GIC Private Limited completed the acquisition of Hologic, Inc..
Funds managed by Blackstone Inc. (NYSE:BX), TPG Global, LLC, Abu Dhabi Investment Authority, and GIC Private Limited have completed the acquisition of Hologic, Inc. (NasdaqGS:HOLX) for $17.2 billion. Hologic's common stock ceased trading and was delisted from Nasdaq, and José E. Almeida has been appointed as the new CEO.
Casey’s joining S&P 500 on Thursday
Casey’s General Stores Inc. is set to join the S&P 500 on Thursday, replacing Hologic Inc., which is being acquired. Casey’s shares rose after the announcement and the company recently reported a significant increase in net income for its third quarter, up 49.3% to $130.1 million. The convenience store chain is also the third-largest c-store retailer and fifth-largest pizza chain in the U.S., with plans for continued growth.
Paramount Skydance Stock Jumps 9% on $24B Gulf Funding for Warner Bros Takeover Bid
Paramount Skydance shares surged nearly 9% after reports confirmed advanced talks for $24 billion in equity commitments from Middle Eastern sovereign wealth funds to finance its $81 billion to $110 billion takeover of Warner Bros. Discovery. This funding package is expected to reduce reliance on debt and aid regulatory scrutiny, de-risking the Warner deal significantly. A special shareholder vote for Warner Bros. Discovery is scheduled for April 23 to approve the transaction, aiming to create a dominant media powerhouse.
BNP Paribas Adjusts TransDigm Group Price Target to $1,700 From $1,900, Maintains Outperform Rating
BNP Paribas has lowered its price target for TransDigm Group (TDG) to $1,700 from $1,900 but continues to maintain an Outperform rating on the stock. This adjustment reflects a revised valuation while the firm still sees strong potential for the aerospace systems and components manufacturer. The article also notes TransDigm Group's recent completion of a $2.2 billion acquisition of Jet Parts Engineering and Victor Sierra Aviation.
North American Construction Group Closes Strategic Acquisition Of Iron Mine Contracting, A Diversified Mining Services Contractor >NOA.T
North American Construction Group (NACG) has completed its acquisition of Iron Mine Contracting, an Aboriginal-owned heavy equipment operator and civil construction contractor based in Fort McMurray, Alberta. This acquisition is part of NACG's strategic plan to expand its mining exposure, diversify its revenue streams, and strengthen its geographic presence in key regions like the Athabasca oil sands. The integration of Iron Mine Contracting into NACG's operations is expected to enhance its service offerings and contribute to future growth.
TransDigm Group Completes $2.2 Billion Acquisition of Jet Parts Engineering and Victor Sierra Aviation Holdings
TransDigm Group (NYSE: TDG) has completed the acquisition of Jet Parts Engineering (JPE) and Victor Sierra Aviation Holdings (VSA) for approximately $2.2 billion in cash. This strategic move, funded by cash on hand and debt offerings, expands TransDigm's presence in the aerospace aftermarket, adding about $280 million in annual revenue to its portfolio. The acquisition strengthens TransDigm's focus on proprietary OEM-alternative parts and repair solutions for commercial, regional, and general aviation sectors.
BNP Paribas Adjusts Howmet Aerospace Price Target to $265 From $280, Maintains Outperform Rating
BNP Paribas has lowered its price target for Howmet Aerospace (HWM) to $265 from $280, while reaffirming its "Outperform" rating on the stock. This adjustment reflects a revised valuation perspective for the aerospace and defense solutions provider. The company continues to receive attention from analysts with other recent price target adjustments and news regarding acquisitions and industry trends.
Nvidia’s (NVDA) Deal With Competitor Marvell (MRVL) Only Strengthens Its Own Ecosystem, Here’s How
NVIDIA Corporation has announced a strategic partnership with Marvell Technology, including a $2 billion investment, to integrate Marvell's custom AI accelerators (XPUs) with NVIDIA's NVLink Fusion AI infrastructure. This collaboration aims to strengthen NVIDIA's AI ecosystem by combining Marvell's XPUs and interconnect solutions with NVIDIA's extensive suite of supporting technologies. Analysts view this deal as a significant move for both companies, boosting Marvell with the investment and further solidifying NVIDIA's position in the AI market.
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Merck has initiated a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc. for $53.00 per share. This follows a definitive agreement announced on March 25, 2026, and is expected to close in the second quarter of 2026, subject to customary conditions including the tender of over 50% of Terns' shares and regulatory approvals. The acquisition will make Terns a wholly owned subsidiary of Merck.
What's Going On With Profusa Stock Tuesday?
Profusa (NASDAQ: PFSA) shares dropped significantly after the company announced its intent to acquire BioInsights' PanOmics multi-omics diagnostics platform in an all-equity deal valued at $30 million. This strategic move aims to expand Profusa's entry into molecular diagnostics, complementing its existing Lumee real-time monitoring system and strengthening its focus on precision medicine, particularly for pancreatic cancer. The deal is subject to due diligence and customary approvals, with Profusa anticipating accelerated development of lab-developed tests and commercialization efforts targeting an estimated $26 million pancreatic cancer market opportunity.
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
Gilead Sciences has acquired German antibody-drug conjugate (ADC) specialist Tubulis GmbH for $3.15 billion in cash plus up to $1.85 billion in potential milestone payments, marking its latest deal to bolster its oncology pipeline. This acquisition brings Tubulis' lead candidate TUB-040, currently in Phase 1b/2 development for ovarian cancer and non-small cell lung cancer, into Gilead's portfolio. Tubulis will operate as a dedicated ADC research and development organization within Gilead, leveraging a partnership initially formed in December 2024.
Devon Energy Surpasses 50 and 200-Day SMAs: Opportunity for Investors?
Devon Energy (DVN) is showing bullish momentum, trading above its 50 and 200-day simple moving averages, driven by a multi-basin portfolio, diversified commodity mix, and rising oil prices. The company's strategic focus on high-margin assets, disciplined acquisition strategy, and low-cost operating model contribute to strong growth potential, improved profitability, and favorable financial metrics. Investors may find this an opportune time to consider DVN, supported by strong earnings estimates and an attractive valuation.
Hologic goes private in $79 per share buyout by Blackstone, TPG
Hologic Inc. has completed its acquisition by Blackstone and TPG, transitioning the women's health company to private ownership in a deal valued at up to $79 per share. Joe Almeida has been appointed CEO, replacing Stephen MacMillan. Stockholders will receive $76 per share in cash plus a contingent value right for up to $3 per share based on future revenue goals, and Hologic's common stock has ceased trading on Nasdaq.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have completed their acquisition of Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, taking the company private in a transaction valued at up to $79 per share. José (Joe) E. Almeida, former Chairman, President, and CEO of Baxter International Inc., has been appointed as the new Chief Executive Officer of Hologic. The acquisition also includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.
MSCI acquires PM Insights to expand private markets data By Investing.com
MSCI Inc. has acquired PM Insights, a private markets data and analytics firm specializing in secondary market reference data for private company securities. This acquisition aims to expand MSCI's presence in private asset investing by providing institutional-grade data, including pricing, valuation, transaction, and liquidity information. The move supports portfolio management, performance measurement, and index creation for private equity investments, with PM Insights' financial results to be integrated into MSCI's Index reportable segment.
Gilead Swallows Another Partner, Paying up to $5.3B for ADC Specialist Tubulis
Gilead Sciences is acquiring German antibody-drug conjugate (ADC) specialist Tubulis GmbH for $3.15 billion in cash plus up to $1.85 billion in potential milestone payments. This acquisition, Gilead's third of the year, aims to bolster its oncology pipeline and includes a promising mid-stage ovarian cancer candidate, TUB-040, which has shown a 59% overall response rate in platinum-resistant ovarian cancer. Tubulis will operate as a dedicated ADC research and development organization within Gilead, leveraging its platform that Gilead was already familiar with through a prior partnership.
UBS Adjusts Price Target on Clorox to $110 From $121, Maintains Neutral Rating
UBS has revised its price target for The Clorox Company (CLX) to $110, down from $121, while maintaining a Neutral rating on the stock. This adjustment comes shortly after Clorox completed its acquisition of GOJO Industries, Inc., expanding its product portfolio with the Purell brand. The article also notes other recent analyst adjustments and company news, including Clorox's exit from the FTSE All-World Index and its regular quarterly dividend declaration.
GE Vernova buys Rostraver warehouse
GE Vernova, formerly part of General Electric, has purchased a 700,000-square-foot distribution center in Rostraver for $70 million, strengthening its presence in Pennsylvania. Township officials are currently unaware of the company's specific plans for the property but expressed enthusiasm for the investment. GE Vernova already operates a factory in Speers and plans to invest $100 million across multiple Pennsylvania facilities, creating 700 new jobs.
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today
Despite a recent decline in revenue due to the temporary boost from its COVID products, Pfizer has been actively expanding its pipeline through significant acquisitions like Seagen and Metsera to secure future growth. The company's stock is currently undervalued, trading at a low valuation despite its blue-chip status and numerous drug candidates in development. Investors who overlook Pfizer at its current price point may regret it in five years due to its potential for significant upside as new assets offset patent cliffs.
Vertex taps Halozyme and its recently acquired Elektrofi tech in $15M drug delivery deal
Vertex Pharmaceuticals has entered a $15 million upfront deal with Halozyme to license its Hypercon microparticle, high-concentration formulation technology, which was developed by Elektrofi. This technology aims to enable reduced injection volumes for drugs and biologics, supporting at-home administration, particularly for "small volume, patient-delivered next-generation biologics." The agreement includes potential milestone payments and royalties for Halozyme, as Vertex seeks to employ the tech across up to three drug targets within its pipeline.
Rollins to acquire Romex Pest Control
Rollins, Inc. announced its acquisition of Romex Pest Control, a move expected to contribute to Rollins' long-term growth strategy by expanding into new regions. Romex, headquartered in Pleasant Grove, Utah, will maintain its brand identity and continue to scale operations while benefiting from Rollins' resources. This acquisition aligns with Rollins' disciplined M&A approach in a fragmented market, and Romex's CEO emphasized their shared commitment to customers and communities.
Nano Dimension sells additively manufactured electronics & Fabrica product lines
Nano Dimension has sold its Additively Manufactured Electronics (AME) and Fabrica product lines to Inspira Technologies for up to $12.5 million. This divestiture aims to maximize shareholder value, optimize the company's cost structure, and reduce cash burn. The decision follows a strategic review and comes despite Nano Dimension previously considering AME a core part of its business.
Sysco Price Target Slashed by Piper Sandler After Surprise $29.1 Billion Restaurant Depot Acquisition
Piper Sandler has cut its price target for Sysco (SYY) from $83 to $77, maintaining a Neutral rating, following Sysco's announcement of a $29.1 billion acquisition of Restaurant Depot. The firm expressed "surprise" at the deal, largely due to concerns over Sysco taking on $21 billion in new debt, pushing its net leverage to 4.5x, and the suspension of share buybacks. Despite management projecting significant EPS accretion and cost synergies, the market has reacted sharply, reflecting skepticism about integration risks and de-leveraging.
BAC vs. PNC: Which Wins When Picking Between Scale & Stability?
This article provides a comparative analysis of Bank of America (BAC) and PNC Financial Services (PNC), two major U.S. banks. It delves into their financial fundamentals, growth strategies, and market performance to help investors decide which stock aligns better with their risk appetite and economic outlook. While BAC offers vast scale and diversified revenue, PNC focuses on a regional banking model with steady earnings.
Kroger, Albertsons sued by Arizona, seven other states seeking antitrust lawsuit expense reimbursement
Arizona and seven other states, along with the District of Columbia, have sued Kroger and Albertsons to recover $10.3 million in expenses incurred battling a failed merger between the two grocery giants. The lawsuit, filed in U.S. District Court in Portland, Oregon, seeks reimbursement for costs associated with their antitrust efforts. Kroger operates Fry's Food Stores and Albertsons owns the Safeway brand in Arizona.
Press Release: EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for up to USD 5.0 Billion
EQT Life Sciences is selling its minority stake in Tubulis to Gilead Sciences, which is acquiring the company for up to USD 5.0 billion. Tubulis specializes in advanced antibody-drug conjugate (ADC) technologies, and this acquisition is expected to bolster Gilead's oncology pipeline. EQT Life Sciences initially invested in Tubulis in 2021 as part of a Series A financing round.
Einride Secures $113M PIPE Financing Ahead of Merger
Einride AB and Legato Merger Corp. III announced an oversubscribed private investment in public equity (PIPE) financing, valued at approximately $113 million, in support of their proposed business combination. The proceeds are expected to fund Einride's technology roadmap and global expansion, including autonomous deployments across North America, Europe, and the Middle East. With this new capital, Einride believes it is well-positioned to scale its commercial deployments, reflecting strong investor confidence in its mission to transform global freight through autonomous and electric technology.
Hershey’s CEO stays ‘hungry’ for growth as snack giant outpaces rivals
Hershey's CEO Kirk Tanner is emphasizing sustained growth by focusing on core brands while expanding into better-for-you and functional foods, which has allowed the company to outpace rivals despite economic headwinds. The snack giant saw a 4.4% sales increase in 2025 to $11.7 billion and anticipates 2.5% to 3.5% organic net sales growth for its current fiscal year. Hershey plans to achieve this through strategic partnerships, innovation in categories like snack mixes, and potential M&A, aiming to capitalize on the resilient and growing snacking market.
Gilead Enters $5 Billion Agreement to Acquire Tubulis
Gilead Sciences has announced an agreement to acquire Tubulis GmbH for up to $5 billion, significantly expanding its oncology pipeline with two clinical-stage antibody-drug conjugate (ADC) assets and a next-generation conjugation platform. This acquisition will establish Munich as Gilead's dedicated ADC research hub and builds on an existing collaboration between the two companies. The deal underscores Gilead's accelerated corporate buildout in oncology, positioning it more strongly in the competitive ADC landscape.
UBS Adjusts Keurig Dr Pepper Price Target to $32 From $36, Maintains Buy Rating
UBS has adjusted its price target for Keurig Dr Pepper (KDP) to $32, down from the previous $36, while reaffirming a Buy rating on the stock. This adjustment comes amidst recent corporate activities, including Keurig Dr Pepper's acquisition of JDE Peet's. The article also notes other recent analyst and rating agency actions concerning Keurig Dr Pepper and JDE Peet's.
Morgan Stanley's new fintech banking head is from Banking's most nomadic team
Morgan Stanley has appointed Georgi Balinov, formerly of Moelis and Silicon Valley Bank, as its global co-head of fintech investment banking. Balinov is part of a team known for its nomadic movement between firms, often following team leader Jason Auerbach. His appointment suggests Morgan Stanley may be preparing for growth in the fintech sector, with potential IPOs like Monzo on the horizon.
UBS Adjusts Price Target on Halliburton to $39 From $35, Maintains Neutral Rating
UBS has increased its price target for Halliburton (NYSE: HAL) to $39 from $35, while keeping a Neutral rating on the stock. This adjustment reflects a revised outlook for the oil-related services company. Halliburton's stock was trading at $37.98, up 0.42%, as of 10:13:06 AM EDT on April 7, 2026.
MSCI’s PM Insights deal adds data on private firms worth $5.5T
MSCI Inc. has acquired PM Insights, a specialist firm providing valuation and other data for private companies that represent over $5.5 trillion in equity market value. This acquisition aims to enhance transparency and provide institutional-grade data and analytics to private asset investing as companies increasingly remain private for extended periods. PM Insights collects proprietary data from a broad network of institutional broker-dealers and bank secondary desks, capturing secondary market activity and equity data crucial for understanding, monitoring, and valuing private equity investments.
ING Ends Russian Unit Sale Amid Doubts On Buyer Approval
Dutch bank ING Groep NV has announced it will not proceed with the sale of its Russian subsidiary, ING Bank (Eurasia) JSC, to Global Development JSC. The decision was made due to an expectation that the Moscow-based buyer would not secure the necessary regulatory approvals for the acquisition. This marks the end of ING's efforts to divest its Russian unit.
Montana insurance agency joins Marsh, keeping staff and offices
Marsh McLennan Agency (MMA) has acquired Seitz Insurance Agency, an independent agency based in Sidney, Montana, specializing in commercial and personal line insurance solutions with a focus on agriculture, crop, and energy industries. All Seitz Insurance employees, including principals David Seitz and Camila Skinner, will join MMA and continue operating from their current offices. This acquisition expands MMA's presence in eastern Montana and allows Seitz Insurance to enhance its offerings while maintaining its community relationships.
MVB Financial (NASDAQ: MVBF) 2026 proxy outlines executive pay, Victor sale bonus, plan share increase
MVB Financial's 2026 proxy statement details upcoming shareholder votes on electing directors, approving executive compensation, increasing shares for the 2022 Stock Incentive Plan, and ratifying their auditor. The proxy outlines a performance-based executive pay program, with a notable one-time $2.1 million consulting payment to CEO Larry Mazza for his role in the $34.2 million pre-tax gain from the sale of Victor Technologies. Shareholders will cast advisory votes on these matters, indicating strong support for current compensation practices in previous years.
What Is Driving Biogen’s Recent Drop and What Comes Next
Biogen (NASDAQ: BIIB) has experienced a significant stock drop since February 2026, falling from around $202 to $172, despite reporting strong Q4 2025 results. This decline is attributed to investor impatience with the company's transition from older, declining multiple sclerosis drugs to newer products like Leqembi and Skyclarys, which, though growing, are not yet fully offsetting the loss of legacy revenue. The company's recent $5.6 billion acquisition of Apellis Pharmaceuticals is a bold move to secure future growth and improve earnings by 2027, but adds short-term merger costs and financial noise, testing investor conviction during this transitional period.
Hologic Announced Transfer or Voluntary Withdrawal of Listing
Hologic (HOLX) has announced its intention to suspend trading and delist its common stock from Nasdaq following a merger. The company plans to file Form 25 for delisting and deregistration, and Form 15 to terminate registration and suspend its Exchange Act reporting obligations. This action was prompted by the completion of its merger.
Competition Bureau reaches agreement with Welltower to protect competition in retirement home industry
The Competition Bureau has reached a consent agreement with Welltower OP LLC to address competition concerns regarding its proposed acquisition of 34 retirement home properties from Amica Senior Lifestyles in Canada. To resolve these concerns, Welltower has agreed to sell four of its existing retirement homes to independent purchasers. This agreement follows scrutiny of Welltower’s recent dominance in the UK care home market by the Competition and Markets Authority (CMA), which is investigating multiple acquisitions by Welltower Inc.
Blackstone and TPG Complete Acquisition of Hologic
Blackstone and TPG have finalized their acquisition of Hologic, a global leader in women’s health, for up to $79 per share, taking the company private. Joe Almeida has been appointed as the new Chief Executive Officer, effective immediately. The transaction, which includes significant minority investments from ADIA and GIC, aims to accelerate Hologic's innovation and growth in medical technologies.
Citigroup Adjusts Norfolk Southern PT to $313 From $300, Maintains Neutral Rating
Citigroup has increased its price target for Norfolk Southern (NSC) to $313, up from $300, while maintaining a "Neutral" rating on the stock. This adjustment comes amidst other analyst revisions for Norfolk Southern, highlighting ongoing recalibrations of expectations for the railroad company. The article also provides a brief company profile and recent news updates related to Norfolk Southern.
Hologic (NASDAQ: HOLX) notifies Nasdaq of listing withdrawal
Hologic Inc. (NASDAQ: HOLX) has filed a Form 25 to notify the Nasdaq Stock Market LLC of the removal and withdrawal of its Common Stock from listing and registration. This action complies with 17 CFR 240.12d2-2 rules. The notification was executed by Nasdaq and signed by Tara Petta, AVP.
Corteva Inc stock: Legal win and split plan spark investor interest
Corteva Inc has secured a significant legal victory with the dismissal of price-fixing claims, removing a major uncertainty as it prepares to split into separate seed and crop protection units by late 2026. This strategic move, coupled with analyst optimism and strong operational EBITDA forecasts, positions Corteva as a compelling investment in the agricultural sector for those seeking exposure to innovation and global food demand. Investors should monitor upcoming shareholder meetings and earnings reports for crucial updates on the split and its implications.
Gilead to acquire Tubulis GmbH for $5B (GILD:NASDAQ)
Gilead Sciences, Inc. announced its intention to acquire German biotechnology firm Tubulis GmbH for $5 billion. This acquisition is aimed at strengthening Gilead's oncology pipeline, specifically by gaining access to Tubulis's antibody-drug conjugate therapies, including those developed for ovarian cancer.
Haymaker Acquisition Corp. 4 (NYSE: HYAC) secures non-redemption and forward share support
Haymaker Acquisition Corp. 4 has secured a significant non-redemption agreement from an existing shareholder, who reversed plans to redeem 250,000 Class A shares and committed to vote in favor of the business combination with Suncrete. Additionally, Haymaker and PubCo entered a Forward Purchase Agreement with Harraden Circle funds for up to 5,000,000 shares, funded from the SPAC trust. These arrangements aim to stabilize cash and voting support for the proposed merger, which received overwhelming approval from both shareholders and warrantholders at recent meetings.
